Peptide Cycling and Tolerance: Do You Actually Need to Take Breaks?

The vocabulary is borrowed. "On cycle", "off cycle" and "eight on, four off" come out of anabolic steroid practice, where they describe something real: exogenous testosterone suppresses the hypothalamic–pituitary–gonadal axis, so the time off exists to let endogenous production recover. That is a suppression problem, and the schedule is a response to it.

None of the peptides in this catalog work that way. A growth-hormone secretagogue does not replace your pituitary's output — it asks the pituitary to release more of what it already makes. BPC-157 and TB-500 do not bind a hormone receptor and do not suppress anything. When the steroid vocabulary was carried across, the schedule came with it and the reason for the schedule did not.

Some receptors do turn themselves down under continuous stimulation. For G-protein-coupled receptors the agonist binds, the receptor is uncoupled from its downstream signalling, and it is then pulled off the cell surface into the cell. Fewer receptors on the surface means the same dose produces a smaller signal. The receptor recycles back to the membrane afterwards, and how fast it recycles decides whether this is a footnote or a real constraint on dosing.

That is genuine pharmacology, it has been measured directly for the ghrelin receptor, and it is the only legitimate basis for cycling anything. The question worth asking of any peptide is not "how many weeks" but "does its receptor do this, and how fast does it come back".

Growth hormone is released in bursts rather than continuously, mostly at night, which made the growth-hormone axis the obvious place to ask whether constant stimulation causes a problem — and the only place where long human dosing studies of a secretagogue were ever run. The generalisation from there happened in forums, not journals: a finding about one receptor became a universal rule applied to molecules with entirely different mechanisms, including ones used for a finite problem where the endpoint is recovery. The specific numbers — eight weeks, twelve weeks, four weeks off — have no trial behind them for any peptide in this catalog.

This is the one place where desensitisation has been watched happen. A 2004 paper in Endocrinology tracked the growth hormone secretagogue receptor subtype 1a after ghrelin binding and reported that it sits at the plasma membrane when unstimulated, desensitises rapidly after stimulation, disappears from the membrane within about twenty minutes and accumulates in the perinuclear region by an hour. The detail that matters is the recovery: unlike most G-protein-coupled receptors, this one recycled slowly, with surface binding returning to control levels after about six hours. A 2010 paper in the American Journal of Physiology – Endocrinology and Metabolism approached it from the other direction, reporting that unsaturated fatty acids prevented desensitisation by blocking internalisation.

Six hours is the number to hold on to. It is why a once-nightly schedule is not the same proposition as continuous exposure, and it is a very long way from "four weeks off".

Hexarelin is the compound the cycling argument was actually tested on. A 1998 study in the Journal of Clinical Endocrinology and Metabolism gave healthy elderly volunteers twice-daily subcutaneous hexarelin for sixteen weeks and measured the growth hormone response to a test dose at intervals. The area under the growth hormone curve was 19.1 µg/L·h at baseline, 13.1 at week one, 12.3 at week four and 10.5 at week sixteen — and 19.4 four weeks after the course ended, statistically indistinguishable from where it started. The attenuation is real, it appears in the first week rather than building over months, it is partial, and it fully reverses.

The same sixteen weeks produced no significant change in IGF-1, IGF binding protein-3, total body fat, lean body mass or bone mineral density. The authors' conclusion was that the biological impact of that schedule on the growth hormone–IGF-1 axis "seems to be minimal".

That cuts both ways. It is the strongest evidence that continuous ghrelin-receptor stimulation turns the receptor down — and also evidence that the thing turned down was a test-dose response rather than an outcome a patient would notice. A 1996 study in the European Journal of Endocrinology found the same pattern in seven short children on intranasal hexarelin: the test-dose response fell by about half within seven days and stayed there, while growth velocity increased anyway across the same months. A falling test-dose response is not the same thing as a treatment that has stopped doing anything.

Two shorter studies in older adults, also published in 1996, used intermittent intranasal or oral hexarelin for eight and fifteen days and found no desensitisation at all. The whole picture is about hours and days, not months: stacking doses inside a receptor-recycling window costs you response, spacing them out does not.

Ipamorelin acts on the same ghrelin receptor, which is why the question follows it. It was described in the European Journal of Endocrinology in 1998 as the first selective growth hormone secretagogue — selective meaning it released growth hormone without the prolactin, ACTH and cortisol rise hexarelin produces. Selectivity is about which pituitary cells respond, not about whether the receptor adapts, so it does not exempt ipamorelin from the mechanism. What does not exist is a sixteen-week ipamorelin study of the kind run on hexarelin, so anyone telling you ipamorelin does or does not desensitise over months is extrapolating from the receptor rather than citing a trial.

This finding usually gets stated backwards. A 2006 study in the Journal of Clinical Endocrinology and Metabolism sampled growth hormone every twenty minutes overnight in healthy men before and a week after a single injection of CJC-1295, a GHRH analog with an eight-day half-life. Continuous GHRH stimulation did not flatten the rhythm: the frequency and magnitude of growth hormone pulses were unaltered. What changed was the trough — basal growth hormone rose about 7.5-fold, mean growth hormone by 46% and IGF-1 by 45%.

That matters for the CJC-1295 / Ipamorelin pairing and the CJC-1295 / Ipamorelin / Sermorelin preparation. The claim that a long-acting GHRH analog destroys pulsatility and therefore needs a break is not what the measurement showed.

Sermorelin is GHRH(1-29), and the relevant human data is a 1997 study in the Journal of Clinical Endocrinology and Metabolism in which nineteen men and women aged 55 to 71 self-injected a GHRH analog nightly for sixteen continuous weeks after a four-week placebo run-in. The growth hormone-releasing effect was sustained throughout — no desensitisation of the pituitary response. Downstream was more interesting: IGF-1 and IGFBP-3 rose within two weeks, stayed elevated for twelve weeks, and were returning toward baseline by week sixteen in both sexes. That is a real, measurable drift under continuous dosing, and precisely the change a repeat IGF-1 draw catches and a calendar does not.

Tesamorelin is the one GHRH analog with a full phase 3 program. The 2007 trial in the New England Journal of Medicine, the pooled phase 3 analysis with safety extension in the Journal of Clinical Endocrinology and Metabolism in 2010, a 2014 randomized trial in JAMA and a 2019 trial in Lancet HIV all dosed once daily, continuously, with no scheduled interruption. Tesamorelin also appears in TITAN and Tesamorelin + Ipamorelin. Where a GHRH analog has been studied properly, continuous dosing is the studied regimen.

No receptor-adaptation mechanism has been established for BPC-157 or TB-500. The published BPC-157 work describes angiogenesis through VEGFR2, nitric oxide signalling and the FAK–paxillin pathway in animal and cell models; the TB-500 literature describes actin sequestration and cell migration. None of that is agonism at a receptor with a documented down-regulation cycle, and no study has reported an attenuating response to repeated dosing. The endpoint for the BPC-157 + TB-500 stack, KLOW or GLOW is the injury, not the calendar.

GHK-Cu is different again. The reason a physician reviews it periodically is not receptor adaptation — it is that the molecule carries copper, and total copper exposure is worth watching in someone taking it continuously alongside other copper-containing products. That is a cumulative-load question with a blood test behind it. The same applies to GHK-Cu inside RADIANCE, REVIVE and ETERNAL.

Thymosin Alpha-1 has a real randomized trial literature — chronic hepatitis B trials from 1998 onward, a 2013 trial in Critical Care, a 2025 phase 3 trial in the BMJ — and those used defined courses tied to an infection, a different structure from cycling: the course ends because the purpose ends. The same logic governs thymosin alpha-1 inside FORTIFY. Selank, Semax and DSIP are the thinnest part of the picture: the Russian clinical work on selank and the DSIP insomnia studies of the 1980s used short defined courses, none designed to answer a tolerance question, and there is no published receptor down-regulation finding for any of the three.

Outside the growth-hormone axis, melanocortins are the clear case. A 2010 study in Peptides infused melanotan II continuously into rat brain and reported a 30% reduction in food intake that attenuated within five days; rats taken off and re-exposed showed a new and equally robust response while rats kept on continuous infusion did not, and MC4 receptor expression was reduced by 25%. That is rodent work with intracerebroventricular infusion, not human subcutaneous dosing, and the outcome measured was food intake rather than the effect Melanotan II is prescribed for — but it is the closest mechanistic case for intermittent melanocortin dosing that exists.

There is no receptor-adaptation argument for semaglutide or tirzepatide at all. These are the best-studied molecules in this catalog by a wide margin, the trials ran 68 weeks and two years without interruption, and the approved labels describe long-term maintenance.

For the molecules with approved counterparts, the labels are unambiguous about duration. Egrifta SV is dosed 1.4 mg subcutaneously once daily, and Egrifta WR 1.28 mg once daily, with no interruption written in. Ozempic is once weekly, with instructions to administer a missed dose within five days and then resume the regular schedule. Zepbound is once weekly, its own indication language is "Weight Reduction and Long-Term Maintenance", and its missed-dose window is four days.

Not one contains a scheduled break, a maximum duration or a drug holiday. Where a regulator has reviewed a full trial package for a peptide medication, the answer has been continuous dosing with response-based continuation.

The exception proves the point. Vyleesi, a melanocortin receptor agonist, is the rare approved peptide whose label caps frequency: no more than one dose in 24 hours, and more than eight doses per month is not recommended, attributed in the label to the risk of focal hyperpigmentation and to the time per month spent with raised blood pressure. The same label directs discontinuation after eight weeks if the patient reports no improvement. That is what a regulator-reviewed limit looks like: a specific number, a stated reason, a stopping rule tied to response. Nothing comparable exists for "eight weeks on, four weeks off".

The FDA maintains a list of bulk drug substances it has identified as potentially presenting significant safety risks in compounding, most recently updated on 22 April 2026. The concerns recorded there are about immunogenicity, peptide-related impurities and the difficulty of characterising the active ingredient — questions of what is in the vial. Not one concerns duration of use, continuous administration, or the absence of scheduled breaks. The agency's interim categories are explained on its 503A bulk substances page, last updated 14 May 2026.

The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and considered BPC-157, KPV, TB-500 and MOTS-c on the first day, and emideltide, Semax and Epitalon on the second. The committee advises and the FDA issues its own determination afterwards; those determinations are pending. The questions before it concerned safety, efficacy and suitability for compounding for specific proposed uses — not how long a patient should take anything. Cycling is not a regulatory concept.